Lindsey Rolfe

3.8k total citations
30 papers, 856 citations indexed

About

Lindsey Rolfe is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Lindsey Rolfe has authored 30 papers receiving a total of 856 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 10 papers in Molecular Biology and 10 papers in Cancer Research. Recurrent topics in Lindsey Rolfe's work include PARP inhibition in cancer therapy (12 papers), Lung Cancer Treatments and Mutations (6 papers) and Cancer, Hypoxia, and Metabolism (5 papers). Lindsey Rolfe is often cited by papers focused on PARP inhibition in cancer therapy (12 papers), Lung Cancer Treatments and Mutations (6 papers) and Cancer, Hypoxia, and Metabolism (5 papers). Lindsey Rolfe collaborates with scholars based in United States, United Kingdom and France. Lindsey Rolfe's co-authors include Heidi Giordano, Sandra Goble, Susan M. Domchek, Amit M. Oza, Kevin Lin, Andrew R. Allen, Rebecca Kristeleit, Lara Maloney, Andrew Hendifar and Ravit Geva and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Lindsey Rolfe

30 papers receiving 834 citations

Peers

Countries citing papers authored by Lindsey Rolfe

Since Specialization

Citations

This map shows the geographic impact of Lindsey Rolfe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lindsey Rolfe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lindsey Rolfe more than expected).

Fields of papers citing papers by Lindsey Rolfe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lindsey Rolfe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lindsey Rolfe. The network helps show where Lindsey Rolfe may publish in the future.

Co-authorship network of co-authors of Lindsey Rolfe

This figure shows the co-authorship network connecting the top 25 collaborators of Lindsey Rolfe. A scholar is included among the top collaborators of Lindsey Rolfe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lindsey Rolfe. Lindsey Rolfe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation 2018 ·JCO Precision Oncology ·Rachna T. Shroff, Andrew Hendifar, Robert R. McWilliams, Ravit Geva, Ron Epelbaum, Lindsey Rolfe, Sandra Goble, Kevin Lin, Andrew V. Biankin, Heidi Giordano, Robert H. Vonderheide, Susan M. Domchek	137
2	A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2 -Mutated Ovarian Carcinoma or Other Solid Tumors 2017 ·Clinical Cancer Research ·Rebecca Kristeleit, Geoffrey I. Shapiro, Howard A. Burris, Amit M. Oza, Patricia LoRusso, Manish R. Patel, Susan M. Domchek, Judith Balmañà, Yvette Drew, Lee-may Chen, Tamar Safra, Ana Fernández Montés, Heidi Giordano, Lara Maloney, Sandra Goble, Jeff Isaacson, Jim Xiao, (unknown), Lindsey Rolfe, Ronnie Shapira‐Frommer	186
3	P2.03-058 Tiger-3: A Phase 3 Randomized Study of Rociletinib Vs Chemotherapy in EGFR-mutated Non-small Cell Lung Cancer (NSCLC) 2017 ·Journal of Thoracic Oncology ·James Chih‐Hsin Yang, Karen L. Reckamp, (unknown), Silvia Novello, Egbert F. Smit, (unknown), Wu‐Chou Su, Wallace Akerley, Collin M. Blakely, Lyudmila Bazhenova, Rita Chiari, Te‐Chun Hsia, Tony Golsorkhi, Darrin Despain, Danny Shih, Lindsey Rolfe, Sanjay Popat, Heather A. Wakelee	2
4	Rociletinib-associated cataracts in EGFR-mutant NSCLC 2016 ·Annals of Oncology ·Zofia Piotrowska, (unknown), Andréa Varga, Manish Thakur, V. Narayanan, Stephen V. Liu, Joel W. Neal, Marshall L. Spiegel, Benjamin Solomon, Helena A. Yu, (unknown), Vassiliki A. Papadimitrakopoulou, Shirish M. Gadgeel, D. Ross Camidge, J.C. Soria, Heather A. Wakelee, Jonathan W. Goldman, Kamden R. Kopani, Lindsey Rolfe, Lecia V. Sequist	2
5	Clinical activity of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with high-grade ovarian carcinoma (HGOC) and a BRCA mutation (BRCAmut): Analysis of pooled data from Study 10 (parts 1, 2a, and 3) and ARIEL2 (parts 1 and 2) 2016 ·Annals of Oncology ·(unknown), Ronnie Shapira‐Frommer, Ana Oaknin, Judith Balmañà, Isabelle Laure Ray-Coquard, Susan M. Domchek, Anna V. Tinker, Cesar M. Castro, Stephen Welch, Andrés Poveda, K.M. Bell-McGuinn, Gottfried E. Konecny, Heidi Giordano, Lara Maloney, Sandra Goble, Lindsey Rolfe, (unknown)	21
6	Updated results from TIGER-X, a phase I/II open label study of rociletinib in patients (pts) with advanced, recurrent T790M-positive non-small cell lung cancer (NSCLC). 2016 ·Journal of Clinical Oncology ·Jonathan W. Goldman, Jean‐Charles Soria, Heather A. Wakelee, D. Ross Camidge, Shirish M. Gadgeel, Helena A. Yu, Karen L. Reckamp, Vassiliki A. Papadimitrakopoulou, M. Pérol, Sai‐Hong Ignatius Ou, Shannon Matheny, Darrin Despain, Jeffrey D. Isaacson, Sergey Yurasov, Lindsey Rolfe, Lecia V. Sequist	9
7	Abstract B102: A phase 2, open-label study of the PARP inhibitor rucaparib in patients with pancreatic cancer and a known deleterious BRCA mutation 2015 ·Cancer Research ·Susan M. Domchek, Robert R. McWilliams, Andrew Hendifar, Rachna T. Shroff, Lawrence Leichman, Ron Epelbaum, Ravit Geva, George Kim, Steven R. Alberts, Robert A. Wolff, Andrew R. Allen, Heidi Giordano, Mitch Raponi, Jeff Isaacson, Lindsey Rolfe, Andrew V. Biankin, Robert H. Vonderheide	3
8	Results of ARIEL2: A Phase 2 trial to prospectively identify ovarian cancer patients likely to respond to rucaparib using tumor genetic analysis. 2015 ·Journal of Clinical Oncology ·Iain A. McNeish, Amit M. Oza, Robert L. Coleman, Clare L. Scott, Gottfried E. Konecny, Anna V. Tinker, David M. O’Malley, James D. Brenton, Rebecca Kristeleit, Katherine M. Bell‐McGuinn, Ana Oaknin, Alexandra Léary, Kevin Lin, Mitch Raponi, Heidi Giordano, Sandra Goble, Lindsey Rolfe, Roman Yelensky, Andrew R. Allen, Elizabeth M. Swisher	71
9	2701 Quantification of genomic loss of heterozygosity enables prospective selection of ovarian cancer patients who may derive benefit from the PARP inhibitor rucaparib 2015 ·European Journal of Cancer ·Kevin Lin, James Sun, Lara Maloney, Sandra Goble, Amit M. Oza, Roger Coleman, Clare L. Scott, Liliane Robillard, E Mann, (unknown), Thomas Harding, Heidi Giordano, Lindsey Rolfe, Iain A. McNeish, Elizabeth M. Swisher, Roman Yelensky, Andrew R. Allen, Mitch Raponi	13
10	A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression 2014 ·Pancreatology ·(unknown), Shubham Pant, David P. Ryan, Daniel A. Laheru, Nathan Bahary, Tomislav Dragovich, Peter J. Hosein, Lindsey Rolfe, Muhammad Wasif Saif, (unknown), Kenneth H. Yu, Maeve A. Lowery, Andrew R. Allen, Eileen M. O’Reilly	19
11	215 Updated clinical and preliminary correlative results of ARIEL2, a Phase 2 study to identify ovarian cancer patients likely to respond to rucaparib 2014 ·European Journal of Cancer ·E. Swisher, James D. Brenton, (unknown), Amit M. Oza, Robert L. Coleman, David M. O’Malley, Gottfried E. Konecny, Lin Ma, Maria I. Harrell, (unknown), Andrea Wahner Hendrickson, (unknown), Mitch Raponi, E Mann, Heidi Giordano, Lara Maloney, Lindsey Rolfe, Iain A. McNeish	9
12	First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M). 2014 ·Journal of Clinical Oncology ·Lecia V. Sequist, Jean‐Charles Soria, Shirish M. Gadgeel, Heather A. Wakelee, D. Ross Camidge, Andréa Varga, Benjamin Solomon, Vassiliki A. Papadimitrakopoulou, Sarah Jaw‐Tsai, (unknown), Paramjit Kaur, Lindsey Rolfe, Andrew R. Allen, Jonathan W. Goldman	111
13	A phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors. 2014 ·Journal of Clinical Oncology ·Jean‐Charles Soria, Filippo de Braud, Ratislav Bahleda, Bárbara Adamo, (unknown), (unknown), (unknown), Jeffrey D. Isaacson, Jason B. Litten, Andrew R. Allen, Lindsey Rolfe, Josep Tabernero	8
14	A Phase 1 Comparative Pharmacokinetic and Cardiac Safety Study of Two Intravenous Formulations of CO-101 in Patients With Advanced Solid Tumors 2013 ·The Journal of Clinical Pharmacology ·Frederik E. Stuurman, Martijn P. Lolkema, A. D. R. Huitema, Patricia M.M.B. Soetekouw, (unknown), Lindsey Rolfe, Paramjit Kaur, Jos H. Beijnen, Harm van Tinteren, Emile E. Voest, Jan H.M. Schellens	10
15	A multicenter, randomized, controlled study of CO-1.01 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) and low tumor expression of human equilibrative nucleoside transporter-1 (hENT1) determined by metastasis biopsy. 2011 ·Journal of Clinical Oncology ·Tone Ikdahl, Ірина Давиденко, Claudio Bassi, (unknown), L Smith, Sue Anne McLachlan, Steven J.M. Jones, Mitch Raponi, Jeffrey D. Isaacson, (unknown), Lindsey Rolfe, (unknown), Elizabeth Poplin	4
16	Recent Pharmacological Advances: Focus on Small-cell Lung Cancer 2010 ·SHILAP Revista de lepidopterología ·Christine Galustian, Victoria Sung, (unknown), Lindsey Rolfe, Angus Dalgleish	1
17	Phase I and DCE-MRI evaluation of CDP791, a di-Fab PEG conjugate that inhibits VEGFR2 2007 ·Journal of Clinical Oncology ·Gordon C. Jayson, (unknown), Geoff J.M. Parker, Alan Jackson, Saifee Mullamitha, K Zinkewich-Péotti, (unknown), J.A. Soranson, Lindsey Rolfe	5
18	Phase I Evaluation of CDP791, a PEGylated Di-Fab′ Conjugate that Binds Vascular Endothelial Growth Factor Receptor 2 2007 ·Clinical Cancer Research ·(unknown), Geoff J.M. Parker, Alan Jackson, Saifee Mullamitha, G. Buonaccorsi, Caleb Roberts, Y. Watson, Kelly Davies, (unknown), Lynn Hope, (unknown), Jeremy Lawrance, Juan W. Valle, (unknown), (unknown), J.A. Soranson, Lindsey Rolfe, K Zinkewich-Péotti, Gordon C. Jayson	58
19	Blockade of PDGF receptor beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and increased tumor vascularised volume 2005 ·Journal of Clinical Oncology ·Gordon C. Jayson, (unknown), Saifee Mullamitha, (unknown), M.I. Saunders, (unknown), Jeremy Lawrance, Bernadette M. Carrington, (unknown), Basil Issa, David L. Buckley, Chi Yuen Cheung, Kevin Davies, Y. Watson, K Zinkewich-Péotti, Lindsey Rolfe, Asti Jackson	1
20	Blockade of Platelet-Derived Growth Factor Receptor-Beta by CDP860, a Humanized, PEGylated di-Fab', Leads to Fluid Accumulation and Is Associated With Increased Tumor Vascularized Volume 2004 ·Journal of Clinical Oncology ·Gordon C. Jayson, Geoff J.M. Parker, Saifee Mullamitha, Juan W. Valle, Mark Saunders, (unknown), Jeremy Lawrance, Bernadette M. Carrington, Caleb Roberts, B. Issa, David L. Buckley, (unknown), Kelly Davies, Y. Watson, K Zinkewich-Péotti, Lindsey Rolfe, Alan Jackson	124

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact